Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

about

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

P2860

Q55265285-A871662E-CCF3-4057-A746-47C4947E1B5C

P2860

Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

Item

http://www.wikidata.org/entity/Q54379261

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@en

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@nl

type

Item

label

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@en

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@nl

prefLabel

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@en

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@nl

P1476

Pre-emptive rituximab for Epst ...... tic stem cell transplantation.

@en

P2093

Atsushi Kikuta

http://www.w3.org/2001/XMLSchema#string

Hideki Sano

http://www.w3.org/2001/XMLSchema#string

Hitoshi Ohto

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Mochizuki

http://www.w3.org/2001/XMLSchema#string

Nobuhisa Takahashi

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Ohara

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.

Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis.

T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia

Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Kinetics of Epstein-Barr virus DNA load in different blood compartments of pediatric recipients of T-cell-depleted HLA-haploidentical stem cell transplantation.

How I treat EBV lymphoproliferation.

Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.

P304

973-978

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/PED.13336

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Shogo Kobayashi

P577

2017-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28581032

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

about

P2860

P2860

Pre-emptive rituximab for Epstein-Barr virus reactivation after haplo-hematopoietic stem cell transplantation.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921